ADTX Aditxt, Inc. logo

ADTX Aditxt, Inc.

Healthcare
$0.51-57.80%ClosedMarket Cap: $17,249

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

-0.00

P/S

1.20

EV/EBITDA

-0.10

DCF Value

$5,101.17

FCF Yield

-107703.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

19.9%

Operating Margin

-127821.4%

Net Margin

-362385.7%

ROE

926.0%

ROA

-373.6%

ROIC

-406.3%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$12.2K$-15.9M$
Q4 null$425.00$-4.7M$
FY null$3.2K$-41.7M$
Q3 null$748.00$-24.0M$

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$1,280.00

Target (Median)

$1,280.00

Target Range

$1,280.00 - $1,280.00

0 Strong Buy0 Buy1 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All
HRT FINANCIAL LP10 percent owner
SellMon Apr 27
HRT FINANCIAL LP10 percent owner
SellMon Apr 27
HRT FINANCIAL LP10 percent owner
SellThu Apr 23
HRT FINANCIAL LP10 percent owner
BuyThu Apr 23
HRT FINANCIAL LP10 percent owner
SellThu Apr 23

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

1.06

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

Peers